| James J Stevermer, MD | |
|
110 N Hospital Dr, Fulton, MO 65251-2511 | |
| (573) 642-5911 | |
| (573) 642-3015 |
| Full Name | James J Stevermer |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 110 N Hospital Dr, Fulton, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124061528 | NPI | - | NPPES |
| 207962705 | Medicaid | MO | |
| P00415766 | Other | MO | RAILROAD MEDICARE |
| 080068139 | Other | MO | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD101287 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Compassus-central Missouri | Jefferson city, MO | Hospice |
| University Of Missouri Health Care | Columbia, MO | Hospital |
| Fulton Nursing & Rehab | Fulton, MO | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
| Total Health And Rehabilitation Center Pc | 5991870990 | 27 |
News Archive
Transdel Pharmaceuticals, Inc. and Jan Marini Skin Research, Inc. have entered into a licensing agreement providing JMSR with the exclusive U.S. rights to Transdel's transdermal delivery technology for use in an anti-cellulite cosmeceutical product for the dermatological market.
In a study to be presented Friday, Jan. 27, in the oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, researchers with the Baylor College of Medicine in Houston, Texas, presented the study titled Association between day and month of delivery with maternal-fetal mortality: weekend effect and July phenomenon in current obstetric practice.
In this post in GlobalPost's "Global Pulse" blog, journalist John Donnelly reports on tuberculosis (TB) in Estonia and how the country has significantly reduced the proportion of multi-drug resistant tuberculosis (MDR-TB) cases since 1998. He writes, "The numbers of new TB cases in Estonia were five times that of the Nordic countries in 1998, but the numbers have tumbled since then and last year Estonia had cut that in half, to 2.5 times the number."
GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.
› Verified 6 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
Transdel Pharmaceuticals, Inc. and Jan Marini Skin Research, Inc. have entered into a licensing agreement providing JMSR with the exclusive U.S. rights to Transdel's transdermal delivery technology for use in an anti-cellulite cosmeceutical product for the dermatological market.
In a study to be presented Friday, Jan. 27, in the oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, researchers with the Baylor College of Medicine in Houston, Texas, presented the study titled Association between day and month of delivery with maternal-fetal mortality: weekend effect and July phenomenon in current obstetric practice.
In this post in GlobalPost's "Global Pulse" blog, journalist John Donnelly reports on tuberculosis (TB) in Estonia and how the country has significantly reduced the proportion of multi-drug resistant tuberculosis (MDR-TB) cases since 1998. He writes, "The numbers of new TB cases in Estonia were five times that of the Nordic countries in 1998, but the numbers have tumbled since then and last year Estonia had cut that in half, to 2.5 times the number."
GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James J Stevermer, MD Po Box 843966, Kansas City, MO 64184-3966 Ph: (573) 884-3300 | James J Stevermer, MD 110 N Hospital Dr, Fulton, MO 65251-2511 Ph: (573) 642-5911 |
News Archive
Transdel Pharmaceuticals, Inc. and Jan Marini Skin Research, Inc. have entered into a licensing agreement providing JMSR with the exclusive U.S. rights to Transdel's transdermal delivery technology for use in an anti-cellulite cosmeceutical product for the dermatological market.
In a study to be presented Friday, Jan. 27, in the oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, researchers with the Baylor College of Medicine in Houston, Texas, presented the study titled Association between day and month of delivery with maternal-fetal mortality: weekend effect and July phenomenon in current obstetric practice.
In this post in GlobalPost's "Global Pulse" blog, journalist John Donnelly reports on tuberculosis (TB) in Estonia and how the country has significantly reduced the proportion of multi-drug resistant tuberculosis (MDR-TB) cases since 1998. He writes, "The numbers of new TB cases in Estonia were five times that of the Nordic countries in 1998, but the numbers have tumbled since then and last year Estonia had cut that in half, to 2.5 times the number."
GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.
› Verified 6 days ago
Sophi Thurman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 110 N Hospital Dr, Fulton, MO 65251 Phone: 573-642-5911 Fax: 573-642-3015 | |
Heather L Pierce, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 N Hospital Dr, Fulton, MO 65251 Phone: 573-642-5911 Fax: 573-642-3015 | |
Dr. William P Cravens, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 850 West Hospital Drive, Suite A, Fulton, MO 65251 Phone: 573-592-0337 Fax: 573-592-0711 | |
Brice P Windsor, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2613 Fairway Dr, Fulton, MO 65251 Phone: 573-642-1990 Fax: 573-642-5089 | |
Dr. Rezwan Islam, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 850 N Hospital Dr, Ste D, Fulton, MO 65251 Phone: 573-642-5338 Fax: 573-642-9224 | |
Mark Cameron Dodds, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 110 N Hospital Dr, Fulton, MO 65251 Phone: 573-642-5911 Fax: 573-642-3015 |